Cover Image
市場調查報告書

幼年型類風濕性關節炎(SJIA):開發中產品分析

Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014

出版商 Global Markets Direct 商品編碼 213085
出版日期 內容資訊 英文 67 Pages
訂單完成後即時交付
價格
Back to Top
幼年型類風濕性關節炎(SJIA):開發中產品分析 Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014
出版日期: 2014年01月31日 內容資訊: 英文 67 Pages
簡介

所謂幼年型類風濕性關節炎(SJIA)是發炎性疾病,特徵有間斷性發燒、紅斑皮疹、及持續性關節腫脹疼痛及發炎。主要的症狀有伴隨高燒(39度以上)的極度倦怠感,出現並消失的紅斑皮疹,加上食慾不振、噁心、體重減少、淋巴腺腫、脾臟及肝臟的肥大,喉嚨疼痛等。也有引起患者心臟、肺周圍發炎(心膜炎、胸膜炎),造成心膜液、胸水沈積的現象。

本報告提供幼年型類風濕性關節炎(SJIA)的治療藥開發情形調查分析,提供您開發中產品的概要,臨床實驗的各階段產品概要,再加上主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

幼年型類風濕性關節炎(SJIA)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

開發中的產品:各企業

治療藥的開發企業

  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Biocon Limited
  • Italfarmaco S.p.A.
  • Avesthagen Limited

治療藥的評估

  • 單獨療法的情況
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • abatacept
  • golimumab
  • givinostat
  • etanercept biosimilar
  • adalimumab biosimilar

開發中產品的最新趨勢

暫停的計劃

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC4518IDB

Global Markets Direct's, 'Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, H1 2014', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Juvenile Idiopathic Arthritis (SJIA). Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Systemic Juvenile Idiopathic Arthritis (SJIA).
  • A review of the Systemic Juvenile Idiopathic Arthritis (SJIA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Systemic Juvenile Idiopathic Arthritis (SJIA).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Systemic Juvenile Idiopathic Arthritis (SJIA) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Systemic Juvenile Idiopathic Arthritis (SJIA) Overview
    • Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA) - Overview
    • Pipeline Products for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Therapeutics under Development by Companies
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Products under Development by Companies
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Companies Involved in Therapeutics Development
  • Bristol-Myers Squibb Company
    • Johnson & Johnson
    • Biocon Limited
    • Italfarmaco S.p.A.
    • Avesthagen Limited
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
    • Assessment by Therapeutic Class
  • Drug Profiles
    • abatacept - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • golimumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • givinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etanercept biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • adalimumab biosimilar - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Recent Pipeline Updates
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Dormant Projects
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Product Development Milestones
    • Featured News & Press Releases
      • Sep 03, 2013: Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
      • Jul 25, 2013: CHMP Adopts Positive Opinion For Novartis's Ilaris
      • May 10, 2013: Novartis's Ilaris Receives Approval From FDA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
      • Jan 17, 2013: AbbVie Receives CHMP Positive Opinion For Humira
      • Nov 08, 2012: Bristol-Myers Squibb To Present New Investigational Data On Orencia At 2012 American College Of Rheumatology Annual Scientific Meeting
      • Jul 19, 2012: CHMP Adopted Positive Opinion Recommending Variation To Terms Of Marketing Authorization For Abbott's Humira
      • Jun 06, 2012: Novartis Announces New Data From Two Trials Of ACZ885 At Annual Congress Of EULAR 2012
      • May 29, 2012: Abbott To Present Clinical Data On HUMIRA At Annual Meeting Of European League Against Rheumatism
      • Nov 16, 2011: Novartis Study Shows ACZ885 Provides Substantial Symptom Relief In 84% Of Patients With Most Serious Form Of Childhood Arthritis
      • Sep 28, 2011: Abbott Japan And Eisai Announce Launch Of Humira Prefilled Syringe 20mg/0.4mL
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H1 2014
  • Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Comparative Analysis by Late Stage Development, H1 2014
  • Comparative Analysis by Clinical Stage Development, H1 2014
  • Comparative Analysis by Early Stage Development, H1 2014
  • Products under Development by Companies, H1 2014
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Bristol-Myers Squibb Company, H1 2014
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Johnson & Johnson, H1 2014
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Biocon Limited, H1 2014
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Italfarmaco S.p.A., H1 2014
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Pipeline by Avesthagen Limited, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Stage and Target, H1 2014
  • Number of Products by Stage and Mechanism of Action, H1 2014
  • Number of Products by Stage and Route of Administration, H1 2014
  • Number of Products by Stage and Molecule Type, H1 2014
  • Number of Products by Stage and Therapeutic Class, H1 2014
  • Systemic Juvenile Idiopathic Arthritis (SJIA) Therapeutics - Recent Pipeline Updates, H1 2014
  • Systemic Juvenile Idiopathic Arthritis (SJIA) - Dormant Projects, H1 2014

List of Figures

  • Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA), H1 2014
  • Number of Products under Development for Systemic Juvenile Idiopathic Arthritis (SJIA) - Comparative Analysis, H1 2014
  • Number of Products under Development by Companies, H1 2014
  • Assessment by Monotherapy Products, H1 2014
  • Number of Products by Top 10 Target, H1 2014
  • Number of Products by Stage and Top 10 Target, H1 2014
  • Number of Products by Top 10 Mechanism of Action, H1 2014
  • Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
  • Number of Products by Top 10 Route of Administration, H1 2014
  • Number of Products by Stage and Top 10 Route of Administration, H1 2014
  • Number of Products by Top 10 Molecule Type, H1 2014
  • Number of Products by Stage and Top 10 Molecule Type, H1 2014
  • Number of Products by Top 10 Therapeutic Class, H1 2014
  • Number of Products by Stage and Top 10 Therapeutic Class, H1 2014
Back to Top